14 January 2021 – Kirchner Group is pleased to announce that it acted as an advisor on due diligence to the Alaska Permanent Fund in the recently announced Tessera Therapeutics $230M Series B financing.
According to the announcement Tessera Therapeutics has developed a new technology that has the ability to write therapeutic instructions into the genome to treat diseases at their source. The company will use the latest round of funding to accelerate research and development in the company’s Gene Writing technologies, expand its team, and establish manufacturing and automation capabilities critical for its platform and programs. This investment will accelerate the company’s ability to position multiple therapeutic programs for clinical development.
“It is incredibly exciting to assist investors who are looking at investing in game changing technologies like Tessera,” stated Blair Kirchner of Kirchner Group. “Our ability to complement diligence with deep technical and scientific expertise has been one of our trademarks over the last 35 years.”
Kirchner Group is also proud to note their previous similar roles in the Sana Biotechnology, Inc., Denali Therapeutics (NASDAQ: DNLI), Juno Therapeutics (acquired by Celgene for approx. $9B) and Indigo Agriculture financings.